EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection

Mohammad Ullah Nayan, Brady Sillman, Mahmudul Hasan, Suyash Deodhar, Srijanee Das, Ashrafi Sultana, Nam Thai Hoang Le, Vicente Soriano, Benson Edagwa, Howard E Gendelman

Advanced Drug Delivery Reviews · 2023-09 · 200 · 115009

DOI: 10.1016/j.addr.2023.115009 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2023-09. Verfasst von Mohammad Ullah Nayan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, NE, USA. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents, HIV-1. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 196 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NINDS NIH HHS, NIMH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adherence to daily oral antiretroviral therapy (ART) is a barrier to both treatment and prevention of human immunodeficiency virus (HIV) infection. To overcome limitations of life-long daily regimen adherence, long-acting (LA) injectable antiretroviral (ARV) drugs, nanoformulations, implants, vaginal rings, microarray patches, and ultra-long-acting (ULA) prodrugs are now available or in development. These medicines enable persons who are or at risk for HIV infection to be treated with simplified ART regimens. First-generation LA cabotegravir, rilpivirine, and lenacapavir injectables and a dapivirine vaginal ring are now in use. However, each remains limited by existing dosing intervals, ease of administration, or difficulties in finding drug partners. ULA ART regimens provide an answer, but to date, such next-generation formulations remain in development. Establishing the niche will require affirmation of extended dosing, improved access, reduced injection volumes, improved pharmacokinetic profiles, selections of combination treatments, and synchronization of healthcare support. Based on such needs, this review highlights recent pharmacological advances and a future treatment perspective. While first-generation LA ARTs are available for HIV care, they remain far from ideal in meeting patient needs. ULA medicines, now in advanced preclinical development, may close gaps toward broader usage and treatment options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAnti-HIV AgentsHIV-1FemaleHumansRilpivirineInjections

Stichwörter der Autor:innen

Adverse reactionsAntiretroviral prodrugsHuman immunodeficiency virusIntegrase strand transfer inhibitorsLong-acting slow effective release antiretroviral therapyMedicinal and polymer chemistryNonnucleoside reverse transcriptase inhibitorsNucleoside reverse transcriptase inhibitorsPharmacodynamicsPharmacokinetic testingPre-exposure prophylaxis

Substanzen

RilpivirineAnti-HIV Agents

Autor:innen und Institutionen

  • Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, NE, USA.
  • Department of Pharmaceutical Science, University of Nebraska Medical Center, NE, USA.
  • Department of Pathology and Microbiology, University of Nebraska Medical Center, NE, USA.
  • UNIR Health Sciences School & Medical Center, Madrid, Spain.
  • Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, NE, USA. Electronic address: benson.edagwa@unmc.edu.
  • Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, NE, USA. Electronic address: hegendel@unmc.edu.

Förderung

  • NIAID NIH HHS
  • NINDS NIH HHS
  • NIMH NIH HHS
  • National Institutes of Health

Zitieren

APA

Ullah Nayan, M., Sillman, B., Hasan, M., Deodhar, S., Das, S., Sultana, A., Thai Hoang Le, N., Soriano, V., Edagwa, B., & Gendelman, H. E. (2023). Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection. Advanced Drug Delivery Reviews, 200, 115009. https://doi.org/10.1016/j.addr.2023.115009

Vancouver

Ullah Nayan M, Sillman B, Hasan M, Deodhar S, Das S, Sultana A, et al. Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection. Advanced Drug Delivery Reviews. 2023;200:115009. doi:10.1016/j.addr.2023.115009

BibTeX
@article{UllahNayan2023,
  author = {Ullah Nayan, Mohammad and Sillman, Brady and Hasan, Mahmudul and Deodhar, Suyash and Das, Srijanee and Sultana, Ashrafi and Thai Hoang Le, Nam and Soriano, Vicente and Edagwa, Benson and Gendelman, Howard E},
  title = {Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection},
  journal = {Advanced Drug Delivery Reviews},
  year = {2023},
  volume = {200},
  pages = {115009},
  doi = {10.1016/j.addr.2023.115009}
}
Kostenlos starten →